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t(1;11)(p32;q23) G-banding - Courtesy Melanie Zenger and 
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Clinics and pathology 
Disease 
Acute lymphoblastic leukaemia (ALL),  
biphenotypic acute leukaemia (BAL), acute myeloid 
leukaemia (AML), and myelodysplastic syndrome 
(MDS). 
Note 
36 cases are available to date (Kaneko et al.,1986; 
Gregoire et al., 1987; Selypes and Laszlo, 1987; 
Hagemeijer et al., 1987; Hayashi et al., 1989; Raimondi 
et al., 1989; Shippey et al., 1989; Pui et al., 1990; 
Lampert et al., 1991; Abshire et al., 1992; Bernard et 
al., 1994; Felix et al., 1995; Felix et al., 1998; Harrison 
et al., 1998; Laughlin et al., 1998; Pinto et al., 1998; 
Secker-Walker et al., 1998; Nakamura et al., 2000; von 
Bergh et al., 2000; Chessells et al., 2002; Kim et al., 
2002; Tsujioka et al., 2003; Douet-Guilbert et al.,2005; 
Sagawa et al., 2006; Jeon and Yi, 2009; de Braekeler 
et al., 2010; Shinohara et al., 2010); we have excluded 
from this review a case of t(1;6;11)(p32;q21;q23) in a 
T-cell lymphoma referred as "T-CLL", as it probably 
represents another entity (Mecucci et al., 1988). We
must also keep in mind that some of the 
t(1;11)(p32;q23) above harvested may not all share the 
common genetic event 5' MLL - 3' EPS15: a case of 
t(1;11)(p32;q23), del(5q), +8 in a patient with therapy-
related leukaemia has recently been described without 
MLL rearrangement (Yamamoto et al., 2010). There 
are also 3 paediatric cases (2 ALLs, 1 AML) of 
MLL/EPS15 translocation which were not included in 
this study, due to the lack of clinical data (Meyer et al., 
2006). 
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Phenotype/cell stem origin 
About half cases were ALLs and half cases AMLs. 
There were 17 ALLs, (mainly CD19+, CD10-) 2 
biphenotypic leukaemias, 15 AMLs (of which were 
three M4-AMLs and nine M5-AMLs), and two MDS.  
There were at least nine cases of secondary leukaemia 
(and also 3 cases of "relapse", but each time with a 
different karyotype; e.g. a M1-AML with the classical 
t(8;21)(q22;q22) relapsed 16 months later with a 
t(1;11) as the sole anomaly (Hayashi et al., 1989)). The 
delay before onset of the secondary leukaemia -
including the so-called relapses- was very similar, from 
a case to another, with a median of 16-21 months 
(range 12-24 months), if we exclude a case with an 
interval of 46 years after nuclear bombing (Nakamura 
et al., 2000). The previous disease was a 
haematological malignancy in seven cases (MDS, 
AML, ALL, multiple myeloma, non Hodgkin 
lymphoma (NHL)), a soft tissue tumour in three cases 
(primitive neuroectodermal tumour (PNET), PEComa, 
osteogenic sarcoma), and a breast cancer. The second 
leukaemia was an ALL in 6 cases, and a myeloid 
leukaemia (MDS or AML) in 6 cases. 
Epidemiology 
There was 12 male and 23 female patients (non 
significant: epsilon = 1.86, 0.07 < p < 0.06). However, 
while there was 8 male and 10 female patients in 
myeloid cases, there was only 3 male patients and 13 
female patients with ALL (chi2 = 6.25 p < 0.02). 
Patients median age was 4 years (range 0-76 years); 
thirteen cases (38%) were infant cases (at or under 1 
year of age), seven cases (20%) were between 1 and 0 
years, three cases between 10 and 16, and twelve cases
(1/3) were adult cases. Median age was 7 years in 
myeloid cases versus 1 year in lymphoid cases (ranges 
were 0.2-76 years and 0-63 years respectively, but with 
5 cases and 1 case above 60 years respectively). About 
half of female cases (11/23), but only 2 of 11 male 
cases were congenital leukaemias (diagnosis at or 
before one year of age), although the ranges were 
similar, with cases above the sixties in both genders 
this is not statistically significant (chi2 = 2.77, 0.05 < p 
< 0.10). Median age in female patients was 2-3 years vs 
7 years for male patients, ranges were similar. 
Clinics 




Median survival was 15 months (see figure), with a 
very few long survivors (a patient was still alive 140 
months after diagnosis (Chessells et al., 2002)). Median 
survival for female patients was 28 months, vs 11 
months in male patients; Survival was significantly 
different according to the sex of the patients (chi2 = 
4,66, p < 0.05, log rang test at 16 months). Survival 
curves for ALL and AML cases cross each other, with 
a median survival at 28 months for ALL cases and only
14 months for AML cases, but with no statistical 
significance. There was no correlation between age of 
the patient and survival. All the same and more 
surprisingly, the few patients with a secondary 
leukaemia with data on survival (n=6) did not seem to 
behave more badly than de novo cases. Also, the 
presence or the absence of chromosomal anomalies 




The t(1;11) was the sole anomaly in 19 of 33 
documented cases (57%), equally distributed between 
ALL and AML cases. There was two complex (three 
way) translocations: a t(1;11;4)(p32;q23q13;p16) and  
t(1;11;10)(p32;q23;q24) (Selypes and Laszlo, 1987; de 
Braekeleer et al., 2010). 
Additional anomalies 
A trisomy 8 was found in four cases, a trisomy 21 in 
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Karyotypes were similar in ALL and myeloid cases, 
apart from that trisomy 8 was found as an 
accompanying anomaly in 3 myeloid and only one 
lymphoid cases, and that the cases with either del(5q) 
or -7 were found in myeloid cases. A complex 
karyotype was present in two myeloid cases. 
Genes involved and proteins 
EPS15 (epidermal growth factor 




A major transcript of 5225 bp produces a 896 amino 
acids protein from 25 exons; at least 5 other splice 
variants from 30 different exons. Contains from N-term 
to C-term: 3 EH (Eps15 Homology) domains (protein-
protein interaction modules) with calcium-binding 
domains (EF hand domains), binding sites to adaptins, 
SH3 binding site, prolin-rich motifs, ubiquitin 
interacting motifs (UIM), and a nuclear export signal in 
C-term. There are also DPF repeats in the C-term third
of the protein. Membrane receptor tyrosine kinase 
signaling inhibition is accomplished by ligand/receptor 
complexes internalization, subsequent trafficking to 
lysosomes and ubiquitination. EPS15 is involved in th s
process. EPS15 has a role in clathrin-mediated 
endocytosis, and may also have a role in transcriptional 






A major transcript of 14982 bp produces a 3969 amino 
acids protein from 36 of the 37 exons. Contains from 
N-term to C-term a binding site for MEN1, 3 AT hooks 
(binds to the minor grove of DNA); 2 speckled nuclear 
localisation signals; 2 repression domains RD1 and 
RD2: RD1 or CXXC: cystein methyl transferase, binds 
CpG rich DNA, has a transcriptional repression 
activity; RD2 recruits histone desacetylases HDAC1 
and HDAC2; 3 plant homeodomains (cystein rich zinc 
finger domains, with homodimerization properties), 1 
bromodomain (may bind acetylated histones), and 1 
plant homeodomain; these domains may be involved in 
protein-protein interaction; a FYRN and a FRYC 
domain; a transactivation domain which binds CBP; 
may acetylates H3 and H4 in the HOX area; a SET 
domain: methyltransferase; methylates H3, including 
histones in the HOX area for allowing chromatin to be 
open to transcription. MLL is cleaved by taspase 1 into
2 proteins before entering the nucleus: a p300/320 N-
term protein called MLL-N, and a p180 C-term protein, 
called MLL-C. The FYRN and a FRYC domains of 
native MLL associate MLL-N and MLL-C in a stable 
complex; they form a multiprotein complex with 
transcription factor TFIID. General transcription factor; 
maintains HOX genes expression in undifferentiated 
cells. Major regulator of hematopoiesis and embryonic 
development; role in cell cycle regulation. 




Variable breakpoint in MLL; fusion of exon 6 to 10 of 
MLL to exon 2 of EPS15 in most studied cases; in one
case the fusion exon of EPS15 was exon 12, but it also 
retains the coiled-coil domain of EPS15; in other cases, 
the breakpoint is upstream exon 1. 
Fusion protein 
Oncogenesis 
The coiled-coil domains of EPS15 mediates 
oligomerization, activating MLL, and MLL-EPS15 
activates Hox gene expression (So et al., 2003). 
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